Sydnexis sells EMEA royalty rights to Ligand for $23 million

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. LRCX
7. SAP
8. CSX
9. ELV
10. NDAQ

Go back to Sydnexis sells EMEA royalty rights to Ligand for $23 million

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

September 22, 2026 9:02 AM EDT

$23 million upfront payment immediately monetizes future royalties associated with Ryjunea in Europe, the Middle East, and Africa

Capital further strengthens Sydnexis balance sheet as Company continues to advance SYD-101 through U.S. regulatory process and prepares for potential commercialization in 2027

DEL MAR, Calif.--(BUSINESS WIRE)-- Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to sell its royalty rights associated... More